Drug reference
Galcanezumab is a humanised monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, inhibiting the function of CGRP at its receptor, and thereby preventing migraine attacks.
PDF page 521
Prophylaxis of migraine [in patients who have at least 4 migraine days per month] (initiated by a specialist) ▶BY SUBCUTANEOUS INJECTION ▶Adult: Loading dose 240 mg for 1 dose, then maintenance 120 mg once a month, maintenance dosing to start 1 month after loading dose. Review treatment 3 months after initiation
PDF page 521
Galcanezumab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1; manufacturer advises to record the brand name and batch number after each administration. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2-8°C) and protect from light—consult product literature for further information regarding storage outside refrigerator.
PDF page 521
▶Common or very common Constipation. skin reactions. vertigo
PDF page 521
Manufacturer advises avoid—limited information available.
PDF page 521
Manufacturer advises avoid during first few days after birth—possible risk from transfer of antibodies to infant. After this time, use during breast- feeding only if clinically needed.
PDF page 521
Manufacturer advises injection into the abdomen, thigh, back of the upper arm, or the gluteal region. Patients may self-administer Emgality ® after appropriate training in subcutaneous injection technique.
PDF page 521
There can be variation in the licensing of different medicines containing the same drug. Solution for injection EXCIPIENTS: May contain Polysorbates A ▶Emgality (Eli Lilly and Company Ltd) Galcanezumab 120 mg per 1 ml Emgality 120mg/1ml solution for injection pre-filled pens | 1 pre-filled disposable injection P £386.50 ERGOT ALKALOIDS
PDF pages 521, 522
Self-administration Manufacturer advises patients and their carers should be given training in subcutaneous injection technique if appropriate. Driving and skilled tasks Manufacturer advises patients and their carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of vertigo.
PDF page 521
Loading dose 240 mg for 1 dose, then
First-line fragment. Read the complete Indications and Dose section above.
PDF page 521
